Cargando…

Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy

Neuroendocrine (NE) tumors include a diverse spectrum of hormone-secreting neoplasms that arise from the endocrine and nervous systems. Current chemo- and radio- therapies have marginal curative benefits. The goal of this study was to develop an innovative antibody-drug conjugate (ADC) to effectivel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Si, Yingnan, Kim, Seulhee, Ou, Jianfa, Lu, Yun, Ernst, Patrick, Chen, Kai, Whitt, Jason, Carter, Angela M., Markert, James M., Bibb, James A., Chen, Herbert, Zhou, Lufang, Jaskula-Sztul, Renata, Liu, Xiaoguang “Margaret”
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854894/ https://www.ncbi.nlm.nih.gov/pubmed/32684623 http://dx.doi.org/10.1038/s41417-020-0196-5

Ejemplares similares

Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment
por: Si, Yingnan, et al.
Publicado: (2020)

2018 Synaptic vesicle 2 receptors as a novel targets for neuroendocrine cancer therapy
por: Jaskula-Sztul, Renata, et al.
Publicado: (2018)

Antibody–Drug Conjugate to Treat Meningiomas
por: Chen, Kai, et al.
Publicado: (2021)

Bioprocess development of antibody-drug conjugate production for cancer treatment
por: Ou, Jianfa, et al.
Publicado: (2018)

Ex Vivo Modeling of Human Neuroendocrine Tumors in Tissue Surrogates
por: Herring, Brendon, et al.
Publicado: (2021)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

Novel biomanufacturing platform for large-scale and high-quality human T cells production
por: Ou, Jianfa, et al.
Publicado: (2019)

Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells
por: Aburjania, Zviadi, et al.
Publicado: (2020)

Chrysin suppresses the achaete-scute complex-like1 and alters the neuroendocrine phenotype of carcinoids
por: Somnay, Yash R., et al.
Publicado: (2015)

Characterization of the far-red fluorescent probe MitoView 633 for dynamic mitochondrial membrane potential measurement
por: Ernst, Patrick, et al.
Publicado: (2023)

Thiocoraline alters neuroendocrine phenotype and activates the Notch pathway in MTC-TT cell line
por: Tesfazghi, Sara, et al.
Publicado: (2013)

Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1
por: Jang, Samuel, et al.
Publicado: (2017)

A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)
por: Zhang, Jiashuai, et al.
Publicado: (2023)

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
por: Si, Yingnan, et al.
Publicado: (2022)

Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
por: Chen, Kai, et al.
Publicado: (2022)

Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo
por: Jang, Samuel, et al.
Publicado: (2017)

Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors
por: Guenter, Rachael E., et al.
Publicado: (2019)

mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer
por: Shahbaz, Muhammad, et al.
Publicado: (2015)

Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry
por: Mizutani, Gou, et al.
Publicado: (2012)

Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
por: Koustoulidou, Sofia, et al.
Publicado: (2022)

Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI
por: Arnfield, Evyn G., et al.
Publicado: (2023)

The effect of strength and endurance training on SSTR2 and SSTR5 in patients with colorectal cancer
por: Zanjani, Farhad Safari, et al.
Publicado: (2019)

Management of Gastrointestinal Neuroendocrine Tumors
por: Wang, Rongzhi, et al.
Publicado: (2019)

Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
por: Si, Yingnan, et al.
Publicado: (2021)

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders
por: Harda, Kristof, et al.
Publicado: (2020)

Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
por: Hou, Jiale, et al.
Publicado: (2021)

Faulty Metabolism: A Potential Instigator of an Aggressive Phenotype in Cdk5-dependent Medullary Thyroid Carcinoma
por: Gupta, Priyanka, et al.
Publicado: (2023)

Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis
por: War, Sajad A, et al.
Publicado: (2012)

Voltage-Gated Sodium Channel Na(V)1.7 Inhibitors with Potent Anticancer Activities in Medullary Thyroid Cancer Cells
por: Pukkanasut, Piyasuda, et al.
Publicado: (2023)

Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
por: Ingenerf, Maria, et al.
Publicado: (2023)

Heterogeneity of Vascular Endothelial Cells, De Novo Arteriogenesis and Therapeutic Implications in Pancreatic Neuroendocrine Tumors
por: Ren, Bin, et al.
Publicado: (2019)

Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?
por: Dalm, Simone U., et al.
Publicado: (2017)

Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo
por: Wyche, Thomas P., et al.
Publicado: (2014)

Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
por: Mehta, Shreya, et al.
Publicado: (2015)

Synthesis and preliminary evaluation of octreotate conjugates of bioactive synthetic amatoxins for targeting somatostatin receptor (sstr2) expressing cells
por: Pryyma, Alla, et al.
Publicado: (2021)

Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
por: Wu, Wei, et al.
Publicado: (2020)

Molecular simulations of SSTR2 dynamics and interaction with ligands
por: Gervasoni, Silvia, et al.
Publicado: (2023)

Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma)
por: Yu, Benxia, et al.
Publicado: (2017)

Retracted: Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma)
por: Song, Hao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v9vn09328h01gbvnkvigkkrd0o